Minerva Neurosciences Inc (NERV) Stock Analysis

Minerva Neurosciences Inc (NERV) is a publicly traded company in the HEALTHCARE sector. It trades at $4.75, carries a market capitalization of $228.75M. This page summarizes the public market data, fundamentals, and frequently asked questions for NERV, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Minerva Neurosciences Inc currently has a Neutral sentiment score of 0.09.

About Minerva Neurosciences Inc

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Waltham, Massachusetts, specializing in the development of innovative therapies for central nervous system disorders. The company’s robust pipeline targets significant unmet medical needs in neuropsychiatric conditions, emphasizing its commitment to research and development. By leveraging cutting-edge science, Minerva aims to transform treatment paradigms and improve quality of life for patients facing ...

GNG Research Analysis

GNG Research scores Minerva Neurosciences Inc (NERV) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NERV.

Frequently Asked Questions

Does NERV pay dividends?

Minerva Neurosciences Inc (NERV) does not currently pay a regular dividend.

What is NERV's market cap?

Minerva Neurosciences Inc (NERV) has a market capitalization of $228.75M with a current stock price of $4.75.